Efficacy and safety of using noninsulated microneedle radiofrequency alone versus in combination with polynucleotides for treatment of periorbital wrinkles

In a randomized, double-blind, split-face trial, PN-based fillers demonstrated superior outcomes to HA fillers in improving skin roughness, pore size, and hydration.

“Notably, in a randomized, double-blind, split-face trial, PN-based fillers demonstrated superior outcomes to those of HA fillers in terms of improving skin roughness, pore size, and hydration.”

Rejuran®, a commercially available purified PN, has shown efficacy in treating crow's feet, with improvements substantiated by objective measurements such as the crow's feet grading scale (CFGS), GAIS, standardized photography, and 3D image analysis.

“Rejuran®, a commercially available purified PN, has shown efficacy in treating crow’s feet, with improvements substantiated by objective measurements such as the crow’s feet grading scale (CFGS), GAIS, standardized photography, and 3D image analysis [170].”

In the periorbital region, PN injections were well-tolerated and associated with minimal side effects.

“These benefits were particularly evident in the periorbital region, where PN injections were well-tolerated and associated with minimal side effects [14,170].”

In Yogya et al., no statistically significant differences in maximum wrinkle depth were observed between the PN and control sides at any follow-up time point.

“no statistically significant differences in maximum wrinkle depth were observed between the PN and control sides at any follow-up time point (p>0.05)”

In Yogya et al., wrinkle indentation began to improve earlier on the PN-treated side, with a statistically significant between-group difference at the two-month follow-up.

“wrinkle indentation began to improve earlier on the PN-treated side, with a statistically significant between-group difference evident at the two-month follow-up (p<0.05; p=0.006).”

In Yogya et al., at six months, 51% of subjects reported improvement exceeding 50%.

“51% reported improvement exceeding 50%”

In Yogya et al., at six months, 82% of subjects on both sides reported more than 25% self-assessed improvement.

“82% of subjects on both sides reported more than 25% self-assessed improvement”

Low-risk judgments were assigned to Yogya et al. [7], Jeon et al. [12], and Kim et al. [13].

“Low-risk judgments were assigned to Yogya et al. [7], Jeon et al. [12], and Kim et al. [13].”

DNA fragment Optimizing Technology (DOTTM), developed by PharmaResearch Co. Ltd., has been used in the production of both PN and PDRN formulations.

“DNA fragment Optimizing Technology (DOT™), developed by PharmaResearch Co. Ltd., has been used in the production of both PN and PDRN formulations [24,169,170,171].”

HPT and similar innovations have been adapted for PN-based products.

“More recently, HPT and similar innovations have also been adapted for PN-based products.”